StockTipsArenaBeta

BUY Morepen Laboratories Limited — Ninad Tamhanekar, Motilal Oswal

BUYMorepen Laboratories Limited
Morepen Laboratories share price target & all analyst calls

byNinad Tamhanekar, Motilal OswalHorizon: 1–3 months9 Nov 2026via NDTV Profit

Entry₹99.15Inferred
Target₹108
Total upside +8.93%
Stop lossNot given
CMP₹99.641d ago
Active+0.49%+8.39%upside left 3 mo left
Follow Ninad Tamhanekar for new callsGet alertsWatch MOREPENLAB for new buy/sell callsGet alertsSee 83 other Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 15 Nov, 3:34 am IST
6 supporting1 neutral1 opposing
Supports the BUY call (6)

RSI at 29 — oversold territory

Technicals · rsi·14 Nov · today

Morepen Laboratories has launched its first prescription generic product, Desloratadine Tablets, in the U.S. market and submitted its first ANDA for Sitagliptin Phosphate Tablets to the U.S. FDA.

BSE · Company Update·9 Nov · 5d ago

(opens in new tab)

Morepen Laboratories has entered the U.S. prescription generics market, leveraging its existing API manufacturing capabilities.

NSE · Press Release·9 Nov · 5d ago

(opens in new tab)

Morepen Laboratories reported record Q2 revenue of Rs. 755 Cr and a 273% surge in EBITDA to Rs. 132 Cr.

NSE · Press Release·27 Oct · 3w ago

(opens in new tab)

Morepen Laboratories reported strong Q2 FY27 results with revenue of Rs. 755 Cr (up 81% YoY) and EBITDA of Rs. 132 Cr (up 273% YoY), driven by CDMO growth and improved business mix.

BSE · Company Update·27 Oct · 3w ago

(opens in new tab)
Neutral / worth noting (1)

Morepen Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

NSE · Outcome of Board Meeting·27 Oct · 3w ago

(opens in new tab)
Weighs against the BUY call (1)

MACD below its signal line — bearish momentum

Technicals · macd·14 Nov · today

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Morepen Laboratories

All analyst calls on Morepen Laboratories

More from Ninad Tamhanekar, Motilal Oswal

Every call and its outcome